Otologic Pharmaceutics

company

About

Otologic Pharmaceutics, Inc. is a development stage pharmaceutical company formed specifically to commercialize promising technologies.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$4.09M
Industries
Biotechnology,Information Technology
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders.

OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue to work to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$4.09M
Otologic Pharmaceutics has raised a total of $4.09M in funding over 2 rounds. Their latest funding was raised on Apr 3, 2014 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 3, 2014 Series A $4.09M 1 Accele Venture Partners Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Otologic Pharmaceutics is funded by 1 investors. Accele Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Accele Venture Partners Yes Series A